Close Menu

People in the News

Nov 05, 2019

PredictImmune: Steven Martin

Cambridge, UK-based PredictImmune has appointed Steven Martin to its board. Martin is currently the managing partner of Paxton Advisors, an advisory and consulting firm based in Omaha, Nebraska. He was previously the president and CEO of Blue Cross and Blue Shield of Nebraska, and also belonged to the company's board of directors from 2002 to 2018. Martin was the founding board chair of Think Whole Person Healthcare, a primary care clinic and pharmacy in Nebraska. 

Nov 01, 2019

FDA: Stephen Hahn

Stephen Hahn is expected to be nominated as commissioner of the US Food and Drug Administration by President Trump, the White House said on Nov. 1. Hahn has been the chief medical executive at the MD Anderson Cancer Center since 2018 and a professor of radiation oncology at MD Anderson since 2015. Previously, he was chair of the Department of Radiation Oncology at the University of Pennsylvania, and before that, he was a senior investigator at the National Cancer Institute. Hahn holds a medical degree from Temple University and a BA in biology from Rice University. Following his appointment, Ned Sharpless, current acting commissioner of the FDA, will return to his post as director of the NCI, and Doug Lowy, who took over for Sharpless, will return to be principal deputy director of the NCI.

Oct 31, 2019

NanoString: Don Kania

NanoString Technologies has appointed Don Kania to its board of directors, effective Oct. 30, 2019. Kania has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, he served as CEO, president, and member of the board of directors of FEI Company until its 2016 acquisition by Thermo Fisher Scientific. He also held various positions at Veeco Instruments, ultimately as chief operating officer. Prior to that he held technical and general management positions at Lawrence Livermore National Laboratory and Los Alamos National Laboratory.

Kania currently serves on the board of directors of robotic-assisted surgery firm Intuitive Surgical. He is also on the board of trustees of the Oregon Health & Science University Foundation and serves as an advisor to several privately held life sciences companies. He holds BS, MS, and PhD degrees in physics and engineering from the University of Michigan.

Oct 29, 2019

Atmo Biosciences: Chris Roberts

Chris Roberts has joined the board of Atmo Biosciences as a non-executive director. The Melbourne, Australia-based company is developing an ingestible gas-sensing capsule that can profile gases with the gut for better diagnosis and treatment of gastrointestinal disorders. Robers has more than 40 years of experience in the international medical device business, including as CEO of Cochlear and founding director and executive vice president of ResMed. Since retiring from Cochlear, he has been chairman of OncoSil Medical, as well as non-executive director of Clarity Pharmaceuticals and o'connell Street Associates. 

Oct 29, 2019

MeMed: Frédéric Sweeney

Frédéric Sweeney has joined MeMed as its chief business development officer. He will focus on building strategic partnerships to accelerate market access to the company's technologies, which include the MeMed BV, an immune system, blood-based test that distinguishes bacterial from viral infections, and the MeMed Key platform for measuring multiple proteins with central lab precision at the point of care within minutes. Sweeney was most recently entrepreneur-in-residence at Versant Ventures, and chief buisness officer at Northern Biologics. Prior to that, he was vice president of corporate development and head of strategic financing at BioMérieux. He was head of business development and strategy at T2 Biosystems before that. 

Oct 28, 2019

Roche: Matthew Sause

Roche Diagnostics has named Matthew Sause as president and CEO, North America, effective Nov. 4. He replaces Jack Phillips, who left Roche at the end of August. Sause was previously the senior VP and head of global commercial product strategy at Gilead Sciences. From 2002 to 2014, Sause worked in the diagnostics division at Roche, filling US-based sales roles in molecular diagnostics, commercial operations positions in Asia, and country leadership in Ireland. In 2014, Sause moved to the pharmaceuticals division, where he was president of country operations in Peru and South Korea, before becoming VP and lifecycle leader for Roche's cancer drug Tecentriq.  

Oct 23, 2019

Laboratory for Advanced Medicine: Alan List

Laboratory for Advanced Medicine has appointed Alan List to its board of directors. A practicing oncologist, List currently serves as president and CEO of the Moffitt Cancer Center in Tampa, Florida. Previously he filled various other roles at Moffitt, including, most recently, executive VP and physician-in-chief. List is an active member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. He earned his medical degree from the University of Pennsylvania.

Oct 23, 2019

Progenity: Sami Shihabi

Progenity promoted Sami Shihabi to chief commercial officer. In his new role, Shihabi will oversee the global commercial operations and corporate development strategies for Progenity’s women’s health and precision medicine business units. He will lead all commercial functional areas including sales, marketing, and managed care. Shihabi joined Progenity in 2018 as senior vice president of marketing and portfolio strategy. He previously was chief commercial officer at Prometheus Laboratories.

Oct 21, 2019

Smith & Nephew: Roland Diggelmann

Smith & Nephew announced Roland Diggelmann will become the company's CEO, effective Nov. 1. He replaces Namal Nawana who is leaving the firm to pursue opportunities outside the UK. Diggelmann has been on Smith & Nephew's board as a non-executive director since March 2018. He spent 11 years at Roche. Before that, he was in strategy and leadership roles at Sulzer Orthopedics and Zimmer, now Zimmer Biomet. 

Oct 21, 2019

Myriad Genetics: Mark Pollack

Myriad Genetics has named Mark Pollack as chief medical officer of Myriad Neuroscience. Pollack will start in this new role on Jan. 15, 2020, and will report to Mark Verratti, president of the neuroscience division. In this position, Pollack will be in charge of efforts to integrate the GeneSight pharmacogenetic test into clinical practice. Pollack is a psychiatrist with three decades of experience in clinical psychiatry and neuroscience. He served as professor and chair of the psychiatry department at Rush University Medical Center in Chicaco, and before that he was a psychiatry professor at Harvard Medical School and directed the Center of Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital. 

Oct 17, 2019

Sienna Cancer Diagnostics: Matthew Hoskin, Carl Stubbings

Sienna Cancer Diagnostics announced Matthew Hoskin is stepping down as its CEO. He will be replaced by Carl Stubbings, currently a non-executive director at Sienna. The change is effective immediately. No reason was given for Hoskin's resignation. Stubbings was most recenlty CEO of BCAL, a private company developing a breast cancer diagnostics. 

Oct 16, 2019

Unilabs: Jos Lamers, Michiel Boehmer, and More

Unilabs has appointed Jos Lamers its executive chairman. He is currently the company's CEO. Additionally, Michiel Boehmer, currently Unilabs' regional director south, will become the president and COO of the firm. He will run Unilabs' daily operations, while Lamers will be responsible for its long-term strategy. 

Boehmer's current responsibilities will be shared by Nicolas Ploquin and Luis Menezes. Ploquin, currently CEO of Unilabs' France will be in charge of part of region south as regional director France, Spain, and Benelux. Menezes, currently CEO of Unilabs Portugal, will also be regional director Portugal, Latin America and the Middle East. 

Christian Rebhan, Unilabs CMO and head of customer excellence, will take over charge of the telemedicine unit from Boehmer and will replace Jacques Herber as head of the operations team. Herber is leaving Unilabs.

Lastly, Martin Schlatter, currently Regional Director Centre, also will become Unilabs' chief commercial officer. 

Oct 15, 2019

Anixa BioSciences: Thomas Schlumpberger

Anixa Biosciences has appointed Thomas Schlumpberger as executive VP, diagnostics. Prior to joining Anixa Schlumpberger held executive roles with several diagnostic companies over the past 20 years, including InVitae, Affymetrix (now Thermo-Fisher Scientific), Inivata, and Singulex. 

Oct 15, 2019

Fluxergy: Ali Tinzali

Fluxergy, an Irvine, California-based developer of point-of-care diagnostics systems, has appointed Ali Tinzali as chief commercial officer. Tinzali joins Fluxergy from Hewlett-Packard, where he led corporate-wide global strategy for healthcare and life sciences. He has also worked in corporate development at Applied Biosystems (now Thermo Fisher Scientific). He also worked for Sony where he helped build a healthcare consumables business that was acquired by Stratec.

Oct 14, 2019

Renalytix AI: Chirag Parikh

AI-based kidney disease diagnostic firm Renalytix AI appointed Chirag Parikh to its board. He is the director of the division of nephrology and the Ronald Peterson professor of medicine at the Johns Hopkins School of Medicine. He has published more than 250 original articles, which have been cited more than 35,000 times. 

Oct 10, 2019

Stilla Technologies: Ruth Szebries

Stilla Technologies has appointed Ruth Szebries as general manager and vice president of commercial operations for its newly established US subsidiary in Beverly, Massachusetts. Szebries will oversee operations in the Americas for the Paris, France-based digital PCR developer. Her previous life science industry experience includes positions at Applied Biosystems and Beckman Coulter, leading the US subsidiaries of BGI and Exiqon, and serving for three years at Qiagen, most recently as that firm's senior director for global market development.

Oct 09, 2019

First Light Diagnostics: Angela Caliendo

First Light Diagnostics has added Angela Caliendo to its clinical advisory board. She is an editor at the Journal of Clinical Microbiology, a board member and fellow of the Infectious Diseases Society of America, and a fellow at the American Academy of Microbiology. She currently is a professor and the executive vice chair of the department of medicine at the Warren Alpert Medical School of Brown University. 

Oct 09, 2019

VolitionRx: Phillip Barnes

VolitionRx has appointed Phillip Barnes to its board, replacing Habib Skaff, who resigned effective Oct. 9. Barnes is a British physician and has been a clinician and clinical manager with the UK National Health Service and related academic institutions. 

Oct 08, 2019

Biodesix: James Jett

Biodesix has appointed James Jett as chief medical officer. Jett previously served as CMO at Oncoimmune. Before Onocimmune, Jett worked as a professor of medicine at the Mayo Medical School and the University of Pittsburgh. Jett has also served as a consultant for the National Cancer Institute and as the editor in chief of the Journal of Thoracic Oncology from 2006 to 2013. 

Oct 04, 2019

Meridian Bioscience: Bryan Baldasare

Meridian has appointed Bryan Baldasare to chief financial officer. He was previously the interim CFO, corporate controller, and treasurer and is currently also the executive vice president and chief accounting officer. Baldasare has been with Meridian since 2000, and before that he was a senior audit manager at Arthur Andersen LLP. 

Sep 30, 2019

Sebia: David Martyr, Benoît Adelus

Sebia has appointed David Martyr as chairman of its board of directors. Alongside Jean-Marc Chermette, CEO of Sebia, Martyr will support the firm's strategic vision in its ongoing next stage of growth, the firm said.

Martyr has served as member of the board of ALDA, the Analytical, Life Sciences & Diagnostics Association, for the past 6 years and is currently a member of the advisory group of Novo Holdings. He was CEO of Tecan from 2012 to 2019. Prior to joining Tecan, Martyr held various executive roles at Leica Microsystems, including group president from 2007 until 2011. He was vice president and group executive of Danaher from 2009 until 2011.

Benoît Adelus is stepping down at Sebia, after serving as CEO from 2008 to 2017 and chairman since 2017.

Sep 26, 2019

Becton Dickinson: Vincent Forlenza, Thomas Polen

Becton Dickinson announced that Vincent Forlenza will retire from his position as of Jan. 28, 2020. Forlenza, who has been with BD for 40 years and has led the company as CEO since 2011, will continue to serve as executive chairman of its board of directors. Thomas Polen, the firm's chief operating officer, will take over as CEO. 

Sep 26, 2019

Cofactor Genomics: Natalie LaFranzo

Cofactor Genomics has promoted Natalie LaFranzo to Vice President of Market Development. She has been with the company for three years. Previously, she held roles in product management at Horizon Discovery and in marketing and communications at Red Rock Labs. LaFranzo will also head Cofactor's new predictive immune modeling center in Cambridge, Massachusetts. The facility will be the company's hub for the research and operations team working with Boston-based pharma, RNA, precision medicine, and immunotherapy companies. 

Sep 26, 2019

Sight Diagnostics: Assi Gol, Noga Eshed-Baror

Sight Diagnostics has appointed Assi Gol as its chief commercial officer and Noga Eshed-Baror as its general US manager.

Before joining the executive team, Gol served on Sight’s advisory board and has supported the company since its founding in 2011. Previously, he served as the data intelligence director at Shop Direct, an online retailer in the UK. He also spent seven years at McKinsey & Company in London and Tel-Aviv.

Eshed-Baror will lead Sight's US efforts, including commercialization and hiring. He is a graduate of the Stanford Business School and brings more than 10 years of business experience, having led projects at both Google and McKinsey. 

Sep 25, 2019

Myriad Genetics: Colleen Reitan, Lee Newcomer

Myriad Genetics has elected Colleen Reitan and Lee Newcomer to its board of directors.

Reitan has spent more than 32 years working in the Blue Cross Blue Shield system, most recently as president of plan operations for Health Care Service Corporation (HCSC), a health plan covering 16 million lives. Prior to BCBS, Reitan held several roles of increasing responsibility including executive VP and chief operating officer for HCSC and president and chief operating officer of BCBS of Minnesota. She currently serves on the boards of Alnylam Pharmaceuticals and Cricket Health.

Newcomer is a board-certified oncologist who most recently served as senior VP of oncology and genetics for UnitedHealthcare. Previously, he was chief medical officer and senior VP of health policy and strategy at UnitedHealth Group. He also served as chief medical officer at Vivius. Newcomer currently serves on the board of Cellworks Group and Intervention Insights.

Pages